Moreover, there have been reports of excessive off-label prescribing and misuse [28,29,30,31,32,33], and the GLP-1 RAs have become popular as a cosmetic weight loss drug by celebrities and are widely promoted on social media [34,35,36,37,38,39]
ORFORGLIPRON Eli Lilly (the manufacturer of Mounjaro), has its own oral GLP-1 drug, orforglipron, that according to Eli Lilly, shows people without type two diabetes seeing weight reduction between 14% and 15% over the course of 36 weeks, whereas those with type two diabetes saw weight loss of about 9.6% over the same time frame
In the STEP 4 trial, participants who achieved significant weight loss on semaglutide 2.4 mg were randomized to either continue the medication or switch to placebo
A 2011 analysis published in Pediatrics examined cardiovascular events among stimulant users and found no statistically significant increase in serious cardiac events in adults without pre-existing structural heart disease (adjusted OR 0.83, 95% CI 0.46 to 1.49) [3]
Cultural sensitivity and equity in this scenario entail being respectful of the patients attitude toward the use of the GLP-1 RA, which can be an emotional topic in some
This framework helps providers and patients distinguish expected changes from those requiring intervention